A model system that predicts effective half-life for radiolabeled antibody therapy

Area of Science:

• Immunology and Cancer Therapeutics
• Preclinical Animal Modeling
• Radiopharmaceutical Biodistribution

Background:

• Radiolabeled antibodies are crucial for cancer diagnosis and therapy, with their efficacy dependent on tumor effective half-life and isotope deposition.
• Different species-derived antibodies exhibit varied effective half-lives, impacting tumor radiation dose, a factor not fully assessed by in vitro methods.
• Understanding in vivo antibody behavior is essential for optimizing therapeutic outcomes in radiolabeled antibody treatments.

Purpose of the Study:

• To develop and validate an animal model for evaluating the effective half-life and biodistribution of radiolabeled immunoglobulin G (IgG) from various species.
• To compare the predictive accuracy of the animal model against clinical data for radiolabeled antibody preparations.
• To guide the selection of optimal IgG species for enhanced clinical application in cancer therapy.

Main Methods:

• Development of an animal model to assess the effective half-life and biodistribution of radiolabeled IgG from diverse species.
• Comparison of experimental data from the animal model with existing clinical trial data using identical radiolabeled antibody preparations.
• Analysis of IgG effective half-lives and tissue distributions across species including monkey, rabbit, porcine, goat, sheep, chicken, turkey, bovine, and baboon.

Main Results:

• The animal model demonstrated strong correlation with clinical findings regarding effective half-lives and biodistribution of radiolabeled IgG.
• Monkey, rabbit, and porcine IgG showed the longest effective half-lives, followed by goat and sheep, while chicken and turkey had the shortest.
• Bovine and baboon IgG were identified as promising candidates for clinical use due to predicted long half-lives and favorable biodistribution.

Conclusions:

• The developed animal model serves as an effective in vivo preclinical screen for predicting the tumor effective half-life of antibodies and IgG from diverse species.
• This model aids in guiding the selection of antibody-derived species for improved clinical efficacy and targeted cancer therapy.
• Bovine IgG has been successfully integrated into clinical use, and baboon IgG is poised for clinical testing based on model predictions.